EASL Guidelines Hepatitis B
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. Therefore, the EASL Guidelines for Hepatitis B presents updated recommendations for the optimal management of HBV infection.
Chronic HBV infection is classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. Most importantly, all patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC). This depends on host and viral factors.
Therefore, the main goal of therapy is to improve survival and quality of life. It does this by preventing disease progression, and consequently HCC development. Most importantly, one should monitor treated patients for therapy response and adherence. However, HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Most importantly, future treatment strategies to achieve ‘cure’ of disease and new biomarkers are discussed.
Do you want to learn more about the management and treatment of Hepatitis? Join us at the EASL Viral Hepatitis Conference 2020. Together we can beat liver disease!
Download the EASL Guidelines for Hepatitis B as PDF or as PPT Slide Deck from the right of your screen.